Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 25, 2025HematologyOpen Access

Meta-analysis of the prognostic efficacy of daratumumab combined with standard therapy in high-risk multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

HZHongmei ZhouMZMin ZhangYJYi Jin

Discussion

Loading...

Member takes

Overview

Meta-analysis reveals improved overall survival and progression-free survival with daratumumab in high-risk multiple myeloma, highlighting its efficacy in enhancing treatment.

Key Points

  • Daratumumab combined with standard therapy significantly improves overall survival and progression-free survival in patients with high-risk multiple myeloma.
  • The meta-analysis included 11 studies with 4993 patients, demonstrating higher objective response rates in the experimental group (P < 0.05).
  • Quality assessment indicated all studies had a low to moderate risk of bias, ensuring reliable evidence for clinical application.
  • Results suggest that while daratumumab reduces anemia incidence, it increases the frequency of thrombocytopenia and neutropenia, with overall manageable adverse effects.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/689a0627e6551bb0af8ce04bhttps://doi.org/10.1080/16078454.2025.2532893
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma2016 · 1,449 citations
  2. 2Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant2024 · 11 citations
  3. 3Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma2019 · 1,020 citations
  4. 4Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors2020 · 106 citations
  5. 5Multiple myeloma: signaling pathways and targeted therapy2024 · 63 citations